PDF(Pubmed)
Abstract：
The 2019 Coronavirus disease (COVID-19) vaccine is a major weapon in the fight against the severe acute respiratory syndrome brought about by coronavirus 2 (SARS-CoV-2). The vaccine significantly reduces the risk and severity of infection by SARS-CoV-2. Patients with systemic lupus erythematosus (SLE) need protection from vaccine-preventable diseases including COVID-19. SLE patients have higher rates of severe infections due to immunosuppressive therapies and multiple immunologic defects - both of which are capable of blunting the immune responses after vaccination. In the management of COVID-19, recommendations have been developed to guide adjustments and/or continuation of immunosuppressive therapies for an effective immune response following vaccination with mRNA-based or viral vector-delivered vaccines. Monoclonal antibodies have also become available since December 2021. Here we present three cases of SLE patients who contracted COVID-19 after vaccination. One was managed in ambulatory settings and two required inpatient hospital admission.
摘要：
2019年冠状病毒病（COVID-19）疫苗是对抗冠状病毒2（SARS-CoV-2）带来的严重急性呼吸道综合症的主要武器。该疫苗可显着降低SARS-CoV-2感染的风险和严重程度。系统性红斑狼疮（SLE）患者需要预防疫苗可预防的疾病，包括COVID-19。SLE患者由于免疫抑制疗法和多种免疫缺陷而具有较高的严重感染率-这两者都能够在疫苗接种后使免疫反应减弱。在COVID-19的管理中，已经制定了建议，以指导免疫抑制疗法的调整和/或继续进行，以在接种基于mRNA或病毒载体递送的疫苗后产生有效的免疫反应。自2021年12月以来，单克隆抗体也已可用。在这里，我们介绍了三例SLE患者在接种疫苗后感染COVID-19。一个在门诊环境中进行管理，两个需要住院。
